Advancing novel CNS therapies to address areas of high unmet medical need, such as epilepsy, migraine and pain

View Product Pipeline

Advancing novel CNS therapies to address areas of high unmet medical need, such as epilepsy, migraine and pain

View Product Pipeline
About

We are a clinical stage biopharmaceutical company focused on developing innovative therapeutics to improve the lives of patients with neurological disorders.

Building upon our extensive knowledge of human genetics and diseases caused by mutations in ion channels, known as channelopathies, we are advancing – both independently and with our pharmaceutical collaborators – a novel product pipeline of ion channel modulators to address therapeutic areas of high unmet medical need, such as pain and epilepsy.

Recent Updates:

On September 6, 2018, we hosted a webcast providing an overview of the addition of XEN496 to our clinical pipeline.

Read More

Product Pipeline


* Xenon has entered into key regulatory and manufacturing agreements related to XEN007; it is anticipated that a Phase 2 clinical trial could be initiated after receiving regulatory feedback.


Investors

Visit our Investor page for News Releases, Annual & Quarterly Reports, Webcasts & Events

View Investor Area
Our Management

Learn more about Xenon's management group

View Management
Careers

See current career opportunities

View Careers